NCT01978119 - A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

November 6, 2013

Primary Completion Date

January 28, 2015

Study Completion Date

January 28, 2015

Conditions

Asthma

Interventions

DRUG

FSC

Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period

DRUG

Placebo

Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period

Trial Locations (13)

21029

GSK Investigational Site, Vinnytsia

49005

GSK Investigational Site, Dnipropetrovsk

61039

GSK Investigational Site, Kharkiv

65025

GSK Investigational Site, Odesa

69035

GSK Investigational Site, Zaporizhzhia

69063

GSK Investigational Site, Zaporizhia

76018

GSK Investigational Site, Ivano-Frankivsk

150003

GSK Investigational Site, Yaroslavl

214006

GSK Investigational Site, Smolensk

390026

GSK Investigational Site, Ryazan

440026

GSK Investigational Site, Penza

603011

GSK Investigational Site, Nizhny Novgorod

634050

GSK Investigational Site, Tomsk